Many consumer devices undergo the FDA clearance process, such as LED masks and fitness trackers that have features like ...
The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...
To date, IZERVAY remains the only FDA-approved treatment to demonstrate a statistically significant slowing of GA across two pivotal studies." The approved label update was based on positive ...
The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE® ...
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
Meanwhile, on Tuesday, the FDA informed Indivior that ... to provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate. The views and opinions ...
Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...
The approved label update was based on positive results from the GATHER2 Phase 3 clinical trial, which evaluated the efficacy and safety of IZERVAY through year 2. IZERVAY was approved by the U.S ...
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...